Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transition protein 1 (TNP1) is a small, highly conserved, arginine and lysine-rich, sperm-specific nuclear protein expressed abundantly in elongating and condensing spermatids during spermatogenesis[1][2][3][4][5][6]. It operates as an intermediate replacement for histones, facilitating the transition to protamines, which enable highly compacted chromatin in mature sperm. TNP1’s main function is to relax nucleosomal DNA and promote histone eviction—key steps in chromatin remodeling—where it prepares chromatin for subsequent compaction by protamines[2][6]. Deficiency or dysregulation of TNP1 is linked to impaired sperm motility, abnormal morphology, increased DNA fragmentation, and ultimately, male infertility[1][3][6]. There are no known drugs targeting TNP1, and its primary relevance is as a molecular biomarker and mechanistic contributor in studies of male infertility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transition protein 1 (TNP1).